Safety and Efficacy of Monoclonal Antibodies for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials

Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease

(2021) Nelly Joseph-Mathurin et al.   NEUROLOGY

Towards a Universal Readout for Fluorine-18 Labelled Amyloid Tracers: The CAPTAINs Study

(2021) Gerard N. Bischof et al.   JOURNAL OF NUCLEAR MEDICINE

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

(2021) Sarah F Ackley et al.   BMJ-British Medical Journal

Evaluation of Aducanumab for Alzheimer Disease

(2021) G. Caleb Alexander et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Leveraging Open Science to Accelerate Research

(2021) Kushal T. Kadakia et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

(2021) Konstantinos I. Avgerinos et al.   AGEING RESEARCH REVIEWS

Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease

(2021) Stephen Salloway et al.   NEUROLOGY

Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks

(2021) David S. Knopman et al.   NEUROLOGY

Revisiting FDA Approval of Aducanumab

(2021) G. Caleb Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease

(2021) Billy Dunn et al.   NEW ENGLAND JOURNAL OF MEDICINE

US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

(2021) Vincent Planche et al.   JAMA Neurology

Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting

(2020) Na-Yeon Jung et al.   JOURNAL OF ALZHEIMERS DISEASE

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

(2020) Emerson Y. Chen et al.   JAMA Internal Medicine

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

(2020) Heather Guthrie et al.   JOURNAL OF ALZHEIMERS DISEASE

Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials

(2020) Angela Tian Hui Kwan et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β

(2019) Li Li et al.   JOURNAL OF ALZHEIMERS DISEASE

Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease

(2019) James A R Nicoll et al.   BRAIN

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

(2019) Bernard J. Hanseeuw et al.   JAMA Neurology

ABBY

(2018) Jeffrey L. Cummings et al.   NEUROLOGY

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

(2018) Stephen Salloway et al.   Alzheimers Research & Therapy

The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting

(2017) Ellis Niemantsverdriet et al.   JOURNAL OF ALZHEIMERS DISEASE

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis

(2017) Jia-Jie Mo et al.   Annals of Clinical and Translational Neurology

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease

(2016) Mark Brody et al.   JOURNAL OF ALZHEIMERS DISEASE

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2016) Ross Penninkilampi et al.   Journal of Neuroimmune Pharmacology

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

(2016) Adrian Ivanoiu et al.   Alzheimers Research & Therapy

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

(2016) Marielle Delnomdedieu et al.   Alzheimers Research & Therapy

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

(2016) Milos D. Ikonomovic et al.   Acta Neuropathologica Communications

Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis

(2015) Elizabeth Morris et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease

(2015) Heii Arai et al.   Geriatrics & Gerontology International

Sharing Clinical Trial Data

(2015) Bernard Lo   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study

(2015) Niels Andreasen et al.   PLoS One

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

(2014) Thomas Leyhe et al.   Alzheimers Research & Therapy

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

(2013) Izuru Miyoshi et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease

(2011) Kazunori Uenaka et al.   CLINICAL NEUROPHARMACOLOGY

A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

(2010) Ronald S. Black et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET